Redeye: Clinical Laserthermia Systems - Exciting Year Ahead

Redeye resumes coverage of CLS after the successful SEK 62 million capital raising (where we acted as financial advisor) and produce a base case of SEK 10 per share. Strong investor interest in the rights issue combined with several potential catalysts in the year ahead, in our view, provide an attractive backdrop to the current investment case.

Read more and download the research update: http://bit.ly/39x2RIY

Start following companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. https://www.redeye.se/about/